Published in J Control Release on September 01, 2015
Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy. ACS Nano (2016) 0.82
Novel amphiphilic folic acid-cholesterol-chitosan micelles for paclitaxel delivery. Oncotarget (2016) 0.77
Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system. Int J Nanomedicine (2017) 0.75
Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics (2017) 0.75
Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases. Nanomedicine (Lond) (2016) 0.75
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer (2004) 7.91
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A (2008) 7.06
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev (2010) 5.26
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A (2007) 5.17
Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A (2004) 4.95
In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med (2001) 4.30
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst (2006) 4.27
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 4.22
Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol (2009) 4.06
Nanotechnology applications in cancer. Annu Rev Biomed Eng (2007) 3.88
Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A (2010) 3.41
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol (2013) 3.39
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer (2011) 3.10
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A (2010) 3.03
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev (2012) 2.99
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature (2014) 2.70
Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad Sci U S A (2007) 2.45
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release (2011) 2.37
Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix. Proc Natl Acad Sci U S A (2006) 2.36
A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat Mater (2013) 2.32
PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol (2004) 2.32
A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Cancer Res (2009) 2.30
Nanotechnology and cancer. Annu Rev Med (2008) 2.25
Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release (2005) 2.19
Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev (1983) 1.96
Recent progress in tumor pH targeting nanotechnology. J Control Release (2008) 1.94
Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release (2003) 1.93
Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat Rev Cancer (2014) 1.89
Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release (2003) 1.89
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res (2005) 1.86
Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res (1992) 1.81
Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett (2010) 1.77
A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev (2010) 1.76
Super pH-sensitive multifunctional polymeric micelle. Nano Lett (2005) 1.75
Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano (2011) 1.74
Interaction of nanoparticles with cells. Biomacromolecules (2009) 1.73
Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane. Proc Natl Acad Sci U S A (2008) 1.71
Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol (1998) 1.65
Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res (2011) 1.51
Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther (2006) 1.51
Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Control Release (2008) 1.50
Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep (2009) 1.45
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res (2003) 1.44
pH (low) insertion peptide (pHLIP) inserts across a lipid bilayer as a helix and exits by a different path. Proc Natl Acad Sci U S A (2010) 1.42
TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release (2006) 1.41
pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation. Proc Natl Acad Sci U S A (2010) 1.38
Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm (2009) 1.38
Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. Angew Chem Int Ed Engl (2011) 1.37
Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small (2008) 1.31
Family of pH (low) insertion peptides for tumor targeting. Proc Natl Acad Sci U S A (2013) 1.31
Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A (1995) 1.27
A tumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. Angew Chem Int Ed Engl (2010) 1.26
Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther (2002) 1.25
Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation. Bioconjug Chem (2012) 1.23
pHLIP peptide targets nanogold particles to tumors. Proc Natl Acad Sci U S A (2012) 1.19
Physicochemical characteristics of pH-sensitive poly(L-histidine)-b-poly(ethylene glycol)/poly(L-lactide)-b-poly(ethylene glycol) mixed micelles. J Control Release (2007) 1.18
pHLIP-mediated translocation of membrane-impermeable molecules into cells. Chem Biol (2009) 1.16
Investigating the optimal size of anticancer nanomedicine. Proc Natl Acad Sci U S A (2014) 1.13
Multicolored pH-tunable and activatable fluorescence nanoplatform responsive to physiologic pH stimuli. J Am Chem Soc (2012) 1.13
pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules (2006) 1.13
Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11
Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev (2012) 1.11
Targeting diseased tissues by pHLIP insertion at low cell surface pH. Front Physiol (2014) 1.10
In vivo pH imaging with (99m)Tc-pHLIP. Mol Imaging Biol (2012) 1.09
MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv Mater (2013) 1.06
Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo. Annu Rev Phys Chem (2015) 1.04
Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. J Am Chem Soc (2014) 1.04
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res (2003) 1.02
Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci U S A (2013) 0.99
Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J Med Chem (2004) 0.98
A controlled-release nanocarrier with extracellular pH value driven tumor targeting and translocation for drug delivery. Angew Chem Int Ed Engl (2013) 0.96
pHLIP®-mediated delivery of PEGylated liposomes to cancer cells. J Control Release (2013) 0.95
Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer (1997) 0.94
Targeting breast tumors with pH (low) insertion peptides. Mol Pharm (2014) 0.94
MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm (2007) 0.94
Targeting hypoxia brings breath of fresh air to cancer therapy. Nat Med (2012) 0.89
Noncanonical amino acids to improve the pH response of pHLIP insertion at tumor acidity. Angew Chem Int Ed Engl (2015) 0.89
Acylsulfonamide-Functionalized Zwitterionic Gold Nanoparticles for Enhanced Cellular Uptake at Tumor pH. Angew Chem Int Ed Engl (2015) 0.88
Integration of nanoassembly functions for an effective delivery cascade for cancer drugs. Adv Mater (2014) 0.88
Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. Adv Mater (2013) 0.87
Drug delivery by an enzyme-mediated cyclization of a lipid prodrug with unique bilayer-formation properties. Angew Chem Int Ed Engl (2009) 0.87
Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials (2013) 0.86